Deleterious reproductive effects of nilotinib in mouse model

in Reproduction
View More View Less
  • 1 Department of Histology and Embryology, Ankara University Faculty of Medicine, Ankara, Turkey
  • 2 Center for Assisted Reproduction, Department of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkey
  • 3 Department of Histology and Embryology, Akdeniz University Faculty of Medicine, Antalya, Turkey
  • 4 Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey

Correspondence should be addressed to C Celik-Ozenci; Email: cilerozenci@akdeniz.edu.tr
Restricted access

Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) that is widely used to treat patients with Philadelphia chromosome-positive chronic myeloid leukaemia (CML). TKIs provided a significant improvement in terms of survival rates and disease-free period in CML; however, there is insufficient knowledge about their side effects, including reproductive toxicity. Since nearly half of the CML patients are in their reproductive age, and newly announced indications cover the treatment of the paediatric age groups, concerns arise about the effects of these drugs on the reproductive system, as there are no controlled preclinical studies. We investigated acute and long-term gonadotoxic and teratogenic effects of nilotinib, utilising a mouse model that simulates various clinical scenarios. We observed significant testicular damage in mice receiving nilotinib according to Johnsen’s score analysis. Alterations were observed in female mice’s number of follicles, as the primordial follicle numbers significantly decreased. Proliferating cell number in both genders’ gonads decreased and apoptosis rate increased significantly. The nilotinib-received female and male mice’s pregnancy rates were low compared to controls. A significant decrease in the thickness of the spongiotrophoblast and decidual layers of the placenta was detected in pregnancies consisting of male and/or female mice treated with nilotinib. The results of this study establish a critical point of view for clinical translation and indicate the importance of consulting patients for directing them to fertility preservation and contraception options for both genders before nilotinib treatment.

 

     An official journal of

    Society for Reproduction and Fertility

 

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 87 87 87
Full Text Views 5 5 5
PDF Downloads 4 4 4
  • Abruzzese E, Trawinska MM, Perrotti AP & De Fabritiis P 2014 Tyrosine kinase inhibitors and pregnancy. Mediterranean Journal of Hematology and Infectious Diseases 6 e2014028. (https://doi.org/10.4084/MJHID.2014.028)

    • Search Google Scholar
    • Export Citation
  • Abruzzese E, Trawinska MM, De Fabritiis P & Baccarani M 2016 Management of pregnant chronic myeloid leukemia patients. Expert Review of Hematology 9 781791. (https://doi.org/10.1080/17474086.2016.1205479)

    • Search Google Scholar
    • Export Citation
  • Alizadeh H, Jaafar H, Rajnics P, Khan MI & Kajtar B 2015 Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leukemia Research 39 4751. (https://doi.org/10.1016/j.leukres.2014.10.002)

    • Search Google Scholar
    • Export Citation
  • Aota Y, Udagawa S, Honda T, Okuda Y & Gotoh A 2020 Delivery of a healthy newborn by the partner of a patient with cml undergoing treatment with nilotinib. Gan To Kagaku Ryoho: Cancer and Chemotherapy 47 811813.

    • Search Google Scholar
    • Export Citation
  • Atallah E 2011 Nilotinib cardiac toxicity: should we still be concerned? Leukemia Research 35 577578. (https://doi.org/10.1016/j.leukres.2011.01.021)

    • Search Google Scholar
    • Export Citation
  • Barkoulas T & Hall PD 2018 Experience with dasatinib and nilotinib use in pregnancy. Journal of Oncology Pharmacy Practice 24 121128. (https://doi.org/10.1177/1078155217692399)

    • Search Google Scholar
    • Export Citation
  • Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N & Tsatsaris V 2012 A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs 23 754757. (https://doi.org/10.1097/CAD.0b013e328352a8fe)

    • Search Google Scholar
    • Export Citation
  • Carlier P, Markarian M, Bernard N, Lagarce L, Dautriche A, Bene J, Fouilhe Sam-Lai N & Eftekhari P 2017 Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Archives of Gynecology and Obstetrics 295 269271. (https://doi.org/10.1007/s00404-016-4262-z)

    • Search Google Scholar
    • Export Citation
  • Chen Y, Wang H, Qi N, Wu H, Xiong W, Ma J, Lu Q & Han D 2009 Functions of tam rtks in regulating spermatogenesis and male fertility in mice. Reproduction 138 655666. (https://doi.org/10.1530/REP-09-0101)

    • Search Google Scholar
    • Export Citation
  • Cheon J, Ahn JW, Park KM, Lee G & Jo YS 2016 Teratogenic effect of radotinib: case report. Anticancer Research 36 65996601. (https://doi.org/10.21873/anticanres.11265)

    • Search Google Scholar
    • Export Citation
  • Conchon M, Sanabani SS, Bendit I, Santos FM, Serpa M & Dorliac-Llacer PE 2009 Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. Journal of Hematology and Oncology 2 42. (https://doi.org/10.1186/1756-8722-2-42)

    • Search Google Scholar
    • Export Citation
  • Dou X, Qin Y, Huang X & Jiang Q 2019 Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Oncologist 24 e1141–e1147. (https://doi.org/10.1634/theoncologist.2019-0109)

    • Search Google Scholar
    • Export Citation
  • Go SI, Lee WS, Lee GW, Kang JH, Kang MH, Lee JH & Kim HG 2013 Nilotinib-induced interstitial lung disease. International Journal of Hematology 98 361365. (https://doi.org/10.1007/s12185-013-1398-5)

    • Search Google Scholar
    • Export Citation
  • Griffith JS, Binkley PA, Kirma NB, Schenken RS, Witz CA & Tekmal RR 2010 Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum. Fertility and Sterility 94 25312535. (https://doi.org/10.1016/j.fertnstert.2010.04.018)

    • Search Google Scholar
    • Export Citation
  • Ijiri TW, Mahbub Hasan AK & Sato K 2012 Protein-tyrosine kinase signaling in the biological functions associated with sperm. Journal of Signal Transduction 2012 181560. (https://doi.org/10.1155/2012/181560)

    • Search Google Scholar
    • Export Citation
  • Jensen MR, Brüggen J, Dilea C, Mestan J & Manley PW 2006 AMN107: Efficacy of the Selective Bcr-Abl Tyrosine Kinase Inhibitor in a Murine Model of Chronic Myelogenous Leukemia. American Association for Cancer Research.

    • Search Google Scholar
    • Export Citation
  • Johnsen SG 1970 Testicular biopsy score count – a method for registration of spermatogenesis in human testes: normal values and results in 335 hypogonadal males. Hormones 1 225. (https://doi.org/10.1159/000178170)

    • Search Google Scholar
    • Export Citation
  • Kantarjian HM, O’Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A & Verstovsek S et al. 2003 Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98 26362642. (https://doi.org/10.1002/cncr.11831)

    • Search Google Scholar
    • Export Citation
  • Kierszenbaum AL 2006 Tyrosine protein kinases and spermatogenesis: truncation matters. Molecular Reproduction and Development 73 399403. (https://doi.org/10.1002/mrd.20456)

    • Search Google Scholar
    • Export Citation
  • Mcginnis LK, Carroll DJ & Kinsey WH 2011 Protein tyrosine kinase signaling during oocyte maturation and fertilization. Molecular Reproduction and Development 78 831845. (https://doi.org/10.1002/mrd.21326)

    • Search Google Scholar
    • Export Citation
  • Moslehi JJ & Deininger M 2015 Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. Journal of Clinical Oncology 33 42104218. (https://doi.org/10.1200/JCO.2015.62.4718)

    • Search Google Scholar
    • Export Citation
  • Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Soder O & Jahnukainen K 2007 Inhibition of tyrosine kinases pdgfr and c-kit by imatinib mesylate interferes with postnatal testicular development in the rat. International Journal of Andrology 30 366376; discussion 376. (https://doi.org/10.1111/j.1365-2605.2007.00755.x)

    • Search Google Scholar
    • Export Citation
  • Palani R, Milojkovic D & Apperley JF 2015 Managing pregnancy in chronic myeloid leukaemia. Annals of Hematology 94 S167S 176. (https://doi.org/10.1007/s00277-015-2317-z)

    • Search Google Scholar
    • Export Citation
  • Ransohoff JD & Kwong BY 2017 Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk 17 834851. (https://doi.org/10.1016/j.clml.2017.07.005)

    • Search Google Scholar
    • Export Citation
  • Ross MH & Pawlina W 2016 Histology: A Text and Atlas. Philadelphia: Wolters Kluver Health.

  • Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Fava C & Intermesoli T et al. 2009 Nilotinib for the frontline treatment of ph(+) chronic myeloid leukemia. Blood 114 49334938. (https://doi.org/10.1182/blood-2009-07-232595)

    • Search Google Scholar
    • Export Citation
  • Salem W, Li K, Krapp C, Ingles SA, Bartolomei MS, Chung K, Paulson RJ, Nowak RA & Mcginnis LK 2019 Imatinib treatments have long-term impact on placentation and embryo survival. Scientific Reports 9 2535. (https://doi.org/10.1038/s41598-019-39134-0)

    • Search Google Scholar
    • Export Citation
  • US Food and Drug Administration 2018 Fda approves nilotinib for pediatric patients with newly diagnosed or resistant/intolerant ph+ cml in chronic phase [Online]. US Food and Drug Administration. (available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nilotinib-pediatric-patients-newly-diagnosed-or-resistantintolerant-ph-cml-chronic). Accessed on 12 November 2.

    • Search Google Scholar
    • Export Citation
  • Wan HT, Mruk DD, Tang EI, Xiao X, Cheng YH, Wong EW, Wong CK & Cheng CY 2014 Role of non-receptor protein tyrosine kinases in spermatid transport during spermatogenesis. Seminars in Cell and Developmental Biology 30 6574. (https://doi.org/10.1016/j.semcdb.2014.04.013)

    • Search Google Scholar
    • Export Citation
  • Wang XR, Wang CD, Liu XM, Bao HC, Qu QL & Hao CF 2015 Effect of pdgf-rb antagonist imatinib on endometrial injury repairing in mouse model. Asian Pacific Journal of Tropical Medicine 8 555559. (https://doi.org/10.1016/j.apjtm.2015.06.001)

    • Search Google Scholar
    • Export Citation
  • Woods L, Perez-Garcia V & Hemberger M 2018 Regulation of placental development and its impact on fetal growth – new insights from mouse models. Frontiers in Endocrinology 9 570. (https://doi.org/10.3389/fendo.2018.00570)

    • Search Google Scholar
    • Export Citation
  • Zhou L, You JH, Wu W, Li JM, Shen ZX & Wang AH 2013 Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leukemia Research 37 12161221. (https://doi.org/10.1016/j.leukres.2013.07.020)

    • Search Google Scholar
    • Export Citation